Since 1990, helping busy clinicians master the science and art of caring for people with HIV disease.

Latest News

July 18, 2011

IAS 2011: Initial Results Released on Simplified NRTI-Sparing Strategy: RAL + DRV/r


Initial Results Released on Simplified NRTI-Sparing Strategy: RAL + DRV/r

New information was released on the first day of the 6th IAS Conference on HIV pathogenesis Treatment and Prevention concerning the use of NRTI-sparing regimens. Currently all approved regimens for ARV-naive patients include nucleoside/tide reverse transcriptase inhibitors, sometimes raising concerns of long-term mitochondrial and renal toxicities. Roger Bedimo, chief, Infectious Diseases at VA North Texas Health Care System, presented the 48-week results from RADAR, a randomized open label pilot study of 80 patients assigned to either raltegravir 400mg bid and darunavir/ritonavir 800/100mg qd or tenofovir/emtricitabine 300/200mg qd+ darunavir/ritonavir 800/100mg qd. At 48 weeks the NRTI-sparing regimen compared favorably with TDF/FTC+DRV/RTV, with similar proportions achieving virologic suppression of HIV-1 RNA to <50 copies/ml (88.9% & 81%). No statistically significant differences were noted in change in mean CD4 count, total cholesterol, triglycerides or mean serum creatinine after 48 weeks on treatment. No serious adverse events were considered related to the study medicines. There were 2 virologic failures noted in the RAL group: 1 patient with no resistance mutations, and 1 patient with a single PI mutation (A71T).

Reference: Bedimo R, Drechler H, Turner D, et al. RADAR study: Raltegravir combined with boosted Darunavir has similar safety and antiviral efficacy as tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients [Abstract]. Presented July 18, 2011 at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy. Poster Presentation #MOPE214.


Source: Reporting for PRN News from Rome, Italy: Anita Radix, MD